U.S. investments, and rhetoric, help AstraZeneca seal drug deal with Trump
Government
AstraZeneca CEO Pascal Soriot looked relaxed standing in the Oval Office on Friday as U.S. President Donald Trump unveiled a medicine deal that will lower drug prices for millions of Americans. The hard work had paid off, allowing Soriot to clinch the first agreement for a non-U.S. drugmaker and shield his Anglo-Swedish company from threatened steep tariffs on imports to the U.S. — the world's largest pharmaceuticals market. That moment at the White House was the culmination of public and
din zilele anterioare